Literature DB >> 9361956

Liposomes. Opportunities in drug delivery.

T M Allen1.   

Abstract

Liposomal drug delivery systems markedly alter the biodistribution of their associated drugs by delaying drug clearance, retarding drug metabolism, decreasing the volume of distribution, and shifting the distribution in favour of diseased tissues with increased capillary permeability. This increases the therapeutic indices of the associated drugs, by increasing the drug concentration in solid tumours and regions of infection, and reducing the drug concentration in normal tissues. Three liposomal formulations have been approved for clinical use.

Entities:  

Mesh：

Substances：

Year:  1997        PMID： 9361956     DOI： 10.2165/00003495-199700544-00004

Source DB:  PubMed          Journal:  Drugs        ISSN： 0012-6667            Impact factor:   9.546


  45 in total

1.  Uptake of adriamycin into large unilamellar vesicles in response to a pH gradient.

Authors:  L D Mayer; M B Bally; P R Cullis
Journal:  Biochim Biophys Acta       Date:  1986-05-09

2.  Preclinical trial of doxorubicin entrapped in sterically stabilized liposomes in dogs with spontaneously arising malignant tumors.

Authors:  D M Vail; L D Kravis; A J Cooley; R Chun; E G MacEwen
Journal:  Cancer Chemother Pharmacol       Date:  1997       Impact factor: 3.333

3.  Visceral leishmaniasis in HIV infected patients: treatment with high dose liposomal amphotericin B (AmBisome).

Authors:  R Russo; L C Nigro; S Minniti; A Montineri; L Gradoni; L Caldeira; R N Davidson
Journal:  J Infect       Date:  1996-03       Impact factor: 6.072

4.  Pharmacokinetics of liposomal amphotericin B (AmBisome) versus other lipid-based formulations.

Authors:  V Heinemann; B Kähny; A Debus; K Wachholz; U Jehn
Journal:  Bone Marrow Transplant       Date:  1994       Impact factor: 5.483

5.  Phase I/II clinical and pharmacokinetic evaluation of liposomal daunorubicin.

Authors:  P S Gill; B M Espina; F Muggia; S Cabriales; A Tulpule; J A Esplin; H A Liebman; E Forssen; M E Ross; A M Levine
Journal:  J Clin Oncol       Date:  1995-04       Impact factor: 44.544

6.  Liposomal amphotericin B is toxic to fungal cells but not to mammalian cells.

Authors:  R Mehta; G Lopez-Berestein; R Hopfer; K Mills; R L Juliano
Journal:  Biochim Biophys Acta       Date:  1984-03-14

7.  Liposomal doxorubicin in the treatment of advanced AIDS-related Kaposi sarcoma.

Authors:  J R Bogner; U Kronawitter; B Rolinski; K Truebenbach; F D Goebel
Journal:  J Acquir Immune Defic Syndr (1988)       Date:  1994-05

8.  Tissue distribution and therapeutic effect of intravenous free or encapsulated liposomal doxorubicin on human prostate carcinoma xenografts.

Authors:  J Vaage; E Barberá-Guillem; R Abra; A Huang; P Working
Journal:  Cancer       Date:  1994-03-01       Impact factor: 6.860

9.  Fluorescence imaging studies for the disposition of daunorubicin liposomes (DaunoXome) within tumor tissue.

Authors:  E A Forssen; R Malé-Brune; J P Adler-Moore; M J Lee; P G Schmidt; T B Krasieva; S Shimizu; B J Tromberg
Journal:  Cancer Res       Date:  1996-05-01       Impact factor: 12.701

10.  Tumour uptake of doxorubicin in polyethylene glycol-coated liposomes and therapeutic effect against a xenografted human pancreatic carcinoma.

Authors:  J Vaage; D Donovan; P Uster; P Working
Journal:  Br J Cancer       Date:  1997       Impact factor: 7.640
View more
  46 in total

1.  Differences in the intracellular distribution of acid-sensitive doxorubicin-protein conjugates in comparison to free and liposomal formulated doxorubicin as shown by confocal microscopy.

Authors:  U Beyer; B Rothern-Rutishauser; C Unger; H Wunderli-Allenspach; F Kratz
Journal:  Pharm Res       Date:  2001-01       Impact factor: 4.200

2.  A mathematical model for comparison of bolus injection, continuous infusion, and liposomal delivery of doxorubicin to tumor cells.

Authors:  A W El-Kareh; T W Secomb
Journal:  Neoplasia       Date:  2000 Jul-Aug       Impact factor: 5.715

Review 3.  New technologies for drug delivery across the blood brain barrier.

Authors:  A V Kabanov; E V Batrakova
Journal:  Curr Pharm Des       Date:  2004       Impact factor: 3.116

4.  A novel liposome-based therapy to reduce complement-mediated injury in revascularized tissues.

Authors:  Ledia Goga; Sathnur B Pushpakumar; Gustavo Perez-Abadia; Paul Olson; Gary Anderson; Chirag V Soni; John H Barker; Claudio Maldonado
Journal:  J Surg Res       Date:  2010-10-16       Impact factor: 2.192

5.  Microfluidic preparation of liposomes to determine particle size influence on cellular uptake mechanisms.

Authors:  Abhay U Andar; Renee R Hood; Wyatt N Vreeland; Don L Devoe; Peter W Swaan
Journal:  Pharm Res       Date:  2013-10-03       Impact factor: 4.200

Review 6.  Disposition of drugs in block copolymer micelle delivery systems: from discovery to recovery.

Authors:  Hamidreza Montazeri Aliabadi; Mostafa Shahin; Dion R Brocks; Afsaneh Lavasanifar
Journal:  Clin Pharmacokinet       Date:  2008       Impact factor: 6.447

7.  Efficient array design for sonotherapy.

Authors:  Douglas N Stephens; Dustin E Kruse; Arif S Ergun; Stephen Barnes; X Ming Lu; Katherine W Ferrara
Journal:  Phys Med Biol       Date:  2008-06-30       Impact factor: 3.609

Review 8.  Challenges and breakthroughs in recent research on self-assembly.

Authors:  Katsuhiko Ariga; Jonathan P Hill; Michael V Lee; Ajayan Vinu; Richard Charvet; Somobrata Acharya
Journal:  Sci Technol Adv Mater       Date:  2008-03-13       Impact factor: 8.090

9.  Pulsed-high intensity focused ultrasound and low temperature-sensitive liposomes for enhanced targeted drug delivery and antitumor effect.

Authors:  Sergio Dromi; Victor Frenkel; Alfred Luk; Bryan Traughber; Mary Angstadt; Monica Bur; Jason Poff; Jianwu Xie; Steven K Libutti; King C P Li; Bradford J Wood
Journal:  Clin Cancer Res       Date:  2007-05-01       Impact factor: 12.531

10.  Cell membrane modification for rapid display of bi-functional peptides: a novel approach to reduce complement activation.

Authors:  Ledia Goga; Gustavo Perez-Abadia; Sathnur B Pushpakumar; Daniel Cramer; Jun Yan; Nathan Todnem; Gary Anderson; Chirag Soni; John Barker; Claudio Maldonado
Journal:  Open Cardiovasc Med J       Date:  2010-07-20
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.